Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LIPA | P38571 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20511591 | 1.00 | CYP1A2 (0.47) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL21688950 | 1.00 | CYP1A2 (0.47) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL21688623 | 1.00 | CYP1A2 (0.47) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL21688460 | 1.00 | CYP1A2 (0.47) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL21688611 | 1.00 | CYP1A2 (0.47) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL21688624 | 1.00 | CYP1A2 (0.47) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL21688533 | 1.00 | CYP1A2 (0.47) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL21688519 | 1.00 | CYP1A2 (0.47) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL21688637 | 1.00 | CYP1A2 (0.47) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL21688716 | 1.00 | CYP1A2 (0.47) | CYP1A2ADRB2ADRB1CYP3A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058971-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230056284-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11160870-B2 | Extended release microparticles and suspensions thereof for medical therapy | Graybug Vision, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200230246-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | CYP1A2 2699/4885ADRB2 669/4885ADRB1 561/4885 |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | PDE6C, PDE6A, PDE6D | CYP1A2 2699/4885ADRB2 669/4885ADRB1 561/4885 |
| US-11160870-B2 | Extended release microparticles and suspensions thereof for medical therapy | CHMP4B, EXOSC9, EXOSC5 | CYP1A2 2730/4885ADRB2 1066/4885ADRB1 990/4885 |
| US-20230058971-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | CHMP4B, EXOSC9, EXOSC5 | CYP1A2 2730/4885ADRB2 1066/4885ADRB1 990/4885 |
| US-20200230246-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | CHMP4B, EXOSC9, EXOSC5 | CYP1A2 2730/4885ADRB2 1066/4885ADRB1 990/4885 |
| US-20230056284-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | CHMP4B, EXOSC9, EXOSC5 | CYP1A2 2730/4885ADRB2 1066/4885ADRB1 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.